Alpha Blockers
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Table 2. 2012 AGS Beers Criteria for Potentially
Table 2. 2012 AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults Strength of Organ System/ Recommendat Quality of Recomm Therapeutic Category/Drug(s) Rationale ion Evidence endation References Anticholinergics (excludes TCAs) First-generation antihistamines Highly anticholinergic; Avoid Hydroxyzin Strong Agostini 2001 (as single agent or as part of clearance reduced with e and Boustani 2007 combination products) advanced age, and promethazi Guaiana 2010 Brompheniramine tolerance develops ne: high; Han 2001 Carbinoxamine when used as hypnotic; All others: Rudolph 2008 Chlorpheniramine increased risk of moderate Clemastine confusion, dry mouth, Cyproheptadine constipation, and other Dexbrompheniramine anticholinergic Dexchlorpheniramine effects/toxicity. Diphenhydramine (oral) Doxylamine Use of diphenhydramine in Hydroxyzine special situations such Promethazine as acute treatment of Triprolidine severe allergic reaction may be appropriate. Antiparkinson agents Not recommended for Avoid Moderate Strong Rudolph 2008 Benztropine (oral) prevention of Trihexyphenidyl extrapyramidal symptoms with antipsychotics; more effective agents available for treatment of Parkinson disease. Antispasmodics Highly anticholinergic, Avoid Moderate Strong Lechevallier- Belladonna alkaloids uncertain except in Michel 2005 Clidinium-chlordiazepoxide effectiveness. short-term Rudolph 2008 Dicyclomine palliative Hyoscyamine care to Propantheline decrease Scopolamine oral secretions. Antithrombotics Dipyridamole, oral short-acting* May -
Tamsulosin Hydrochloride
PRODUCT MONOGRAPH Pr SANDOZ TAMSULOSIN Tamsulosin hydrochloride Sustained-Release Capsules 0.4 mg Selective Antagonist of Alpha1A Adrenoreceptor Subtype in the Prostate Sandoz Canada Inc. Date of Revision: 110 Rue de Lauzon October 22, 2019 Boucherville, Québec J4B 1E6 Submission Control No: 232434 Sandoz Tamsulosin Page 1 of 31 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION .......................................................... 3 SUMMARY PRODUCT INFORMATION ................................................................................. 3 INDICATIONS AND CLINICAL USE ....................................................................................... 3 CONTRAINDICATIONS ............................................................................................................ 3 WARNINGS AND PRECAUTIONS .......................................................................................... 4 ADVERSE REACTIONS ............................................................................................................ 6 DRUG INTERACTIONS ........................................................................................................... 10 DOSAGE AND ADMINISTRATION ....................................................................................... 12 OVERDOSAGE ......................................................................................................................... 12 ACTION AND CLINICAL PHARMACOLOGY ..................................................................... 13 STORAGE AND STABILITY -
Appendix A: Potentially Inappropriate Prescriptions (Pips) for Older People (Modified from ‘STOPP/START 2’ O’Mahony Et Al 2014)
Appendix A: Potentially Inappropriate Prescriptions (PIPs) for older people (modified from ‘STOPP/START 2’ O’Mahony et al 2014) Consider holding (or deprescribing - consult with patient): 1. Any drug prescribed without an evidence-based clinical indication 2. Any drug prescribed beyond the recommended duration, where well-defined 3. Any duplicate drug class (optimise monotherapy) Avoid hazardous combinations e.g.: 1. The Triple Whammy: NSAID + ACE/ARB + diuretic in all ≥ 65 year olds (NHS Scotland 2015) 2. Sick Day Rules drugs: Metformin or ACEi/ARB or a diuretic or NSAID in ≥ 65 year olds presenting with dehydration and/or acute kidney injury (AKI) (NHS Scotland 2015) 3. Anticholinergic Burden (ACB): Any additional medicine with anticholinergic properties when already on an Anticholinergic/antimuscarinic (listed overleaf) in > 65 year olds (risk of falls, increased anticholinergic toxicity: confusion, agitation, acute glaucoma, urinary retention, constipation). The following are known to contribute to the ACB: Amantadine Antidepressants, tricyclic: Amitriptyline, Clomipramine, Dosulepin, Doxepin, Imipramine, Nortriptyline, Trimipramine and SSRIs: Fluoxetine, Paroxetine Antihistamines, first generation (sedating): Clemastine, Chlorphenamine, Cyproheptadine, Diphenhydramine/-hydrinate, Hydroxyzine, Promethazine; also Cetirizine, Loratidine Antipsychotics: especially Clozapine, Fluphenazine, Haloperidol, Olanzepine, and phenothiazines e.g. Prochlorperazine, Trifluoperazine Baclofen Carbamazepine Disopyramide Loperamide Oxcarbazepine Pethidine -
Commonly Prescribed Psychotropic Medications
COMMONLY PRESCRIBED PSYCHOTROPIC MEDICATIONS NAME Generic (Trade) DOSAGE KEY CLINICAL INFORMATION Antidepressant Medications* Start: IR-100 mg bid X 4d then ↑ to 100 mg tid; SR-150 mg qam X 4d then ↑ to 150 mg Contraindicated in seizure disorder because it decreases seizure threshold; stimulating; not good for treating anxiety disorders; second Bupropion (Wellbutrin) bid; XL-150 mg qam X 4d, then ↑ to 300 mg qam. Range: 300-450 mg/d. line TX for ADHD; abuse potential. ¢ (IR/SR), $ (XL) Citalopram (Celexa) Start: 10-20 mg qday,↑10-20 mg q4-7d to 30-40 mg qday. Range: 20-60 mg/d. Best tolerated of SSRIs; very few and limited CYP 450 interactions; good choice for anxious pt. ¢ Duloxetine (Cymbalta) Start: 30 mg qday X 1 wk, then ↑ to 60 mg qday. Range: 60-120 mg/d. More GI side effects than SSRIs; tx neuropathic pain; need to monitor BP; 2nd line tx for ADHD. $ Escitalopram (Lexapro) Start: 5 mg qday X 4-7d then ↑ to 10 mg qday. Range 10-30 mg/d (3X potent vs. Celexa). Best tolerated of SSRIs, very few and limited CYP 450 interactions. Good choice for anxious pt. $ Fluoxetine (Prozac) Start: 10 mg qam X 4-7d then ↑ to 20 mg qday. Range: 20-60 mg/d. More activating than other SSRIs; long half-life reduces withdrawal (t ½ = 4-6 d). ¢ Mirtazapine (Remeron) Start: 15 mg qhs. X 4-7d then ↑ to 30 mg qhs. Range: 30-60 mg/qhs. Sedating and appetite promoting; Neutropenia risk (1 in 1000) so avoid in immunosupressed patients. -
Study Protocol and Statistical Analysis Plan
Propranolol and Gene Expression in HCT Protocol v3.0, January 15, 2016 RANDOMIZED CONTROLLED PILOT STUDY USING PROPRANOLOL TO DECREASE GENE EXPRESSION OF STRESS-MEDIATED BETA- ADRENERGIC PATHWAYS IN HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS Version 3.0 Principal Investigator: Jennifer M. Knight, MD Medical College of Wisconsin 8701 Watertown Plank Road Milwaukee, WI 53226 Telephone: 414-955-8908 Fax: 414-955-6285 Email: [email protected] Co-Investigator: J. Douglas Rizzo, MD, MS CIBMTR Froedtert and the Medical College of Wisconsin Clinical Cancer Center 9200 W. Wisconsin Avenue Suite C5500 Milwaukee, WI 53226 Telephone: 414-805-0700 Fax: 414-805-0714 Email: [email protected] Co-Investigator: Parameswaran Hari, MD, MS Froedtert and the Medical College of Wisconsin Clinical Cancer Center 9200 W. Wisconsin Avenue Suite C5500 Milwaukee, WI 53226 Telephone: 414-805-4600 Fax: 414-805-4606 Email: [email protected] Consultant Steve W. Cole, PhD and Statistician: UCLA-David Geffen School of Medicine 10833 LeConte Ave 11-934 Factor Bldg Los Angeles, CA 90095-1678 Telephone: 310-267-4243 Email: [email protected] 1 Propranolol and Gene Expression in HCT Protocol v3.0, January 15, 2016 Sponsor: Medical College of Wisconsin Funding Sponsor: This project has an offer of sponsorship from the National Cancer Institute, National Institutes of Health, under Contract No. HHSN261200800001E. 2 Propranolol and Gene Expression in HCT Protocol v3.0, January 15, 2016 PROTOCOL SYNOPSIS Randomized Controlled Pilot Study Using Propranolol to Decrease Gene Expression of Stress-Mediated Beta-Adrenergic Pathways in Hematopoietic Stem Cell Transplant Recipients Principal Investigator: Jennifer M. Knight, MD Study Design: This is a randomized controlled pilot study designed to evaluate whether the beta-adrenergic antagonist propranolol is effective in decreasing gene expression of stress-mediated beta-adrenergic pathways among a cohort of individuals receiving an autologous hematopoietic stem cell transplant (HCT) for multiple myeloma. -
Avoid the Stop and Go of BPH Start and Stay on RAPAFLO® for BPH Symptom Relief
Avoid the Stop and Go of BPH Start and Stay on RAPAFLO® for BPH Symptom Relief Using RAPAFLO® RAPAFLO® is available only by prescription and is approved to treat male urinary symptoms due to BPH, also called an enlarged prostate. RAPAFLO® should not be used to treat high blood pressure. Important Safety Information Who should not take RAPAFLO® (silodosin) capsules? Do not take RAPAFLO® if you: • have certain kidney problems. • have certain liver problems. Please see additional Important Safety Information throughout this brochure and accompanying full Prescribing Information in pocket. Have BPH symptoms? What they may mean Enlarged prostate— uncomfortable but not uncommon Your doctor has diagnosed you with having BPH, benign prostatic hyperplasia, also known as an enlarged prostate. As men age, having BPH is not unusual. In fact, BPH is the most common prostate problem for men over 50. It affects about 50% of men aged 51-60 and up to 90% of men over 80. The prostate is about But it can grow to the size of a walnut the size of a baseball. in younger men. BLADDER The prostate is located below the bladder and surrounds the urethra, the tube that carries urine from the bladder. BPH symptoms occur when the “smooth” muscle of the prostate squeezes the urethra. This, in turn, can affect your bladder URETHRA control. Unfortunately, there is little you can do PROSTATE to avoid BPH. 2 Is BPH linked to prostate cancer? No. While many men share this belief, BPH is not linked to prostate cancer, and men with BPH are not more likely to get prostate cancer. -
ALLHAT Protocol, Can Enter the Trial at the Discretion of the Principal Investigator Or His/Her Designee
Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Protocol Revised: March 1995 May 1995 April 1998 April 2000 April 2000 Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Protocol Table of Contents Page I. Overview............................................................................................................................ 2 II. Background........................................................................................................................ 4 III. Hypotheses and Study Power ........................................................................................... 10 IV. Eligibility and Exclusions................................................................................................. 13 V. Recruitment....................................................................................................................... 17 VI. Antihypertensive Intervention .......................................................................................... 22 VII. Cholesterol-Lowering Intervention................................................................................... 26 VIII. Laboratory Measurements ................................................................................................ 28 IX. Outcome Measurements.................................................................................................... 30 X. Study Organization .......................................................................................................... -
Medication Dental Watch List Risk for Reflux Risk for Caries
Risk for Stomatitis Risk for Xerostomia Generic and Trade Name Medication Dental Watch List Risk for Reflux Risk for Caries Abilify Celexa Exenatide Itraconazole Naproxen Sinequan Acamprosate Cetirizine Famotidine Ketorolac Neurontin Sporanox Accutane Chantix Feldene Kytril Nexium Strattera Actiq Chlorpromazine Felodipine Lamivudine Nifedipine Subutex Adalat Cholestryramine Fentanyl Lansoprazole Nitro-Bid Sulfamethoxazole Advair Cialis Fentanyl (transmucosal) Levalbuterol Nitro-Dur Sulfasalazine Aldomet Citalopram Flexeril Levbid Nitroglycerin Sulfatrim Alendronate Clarithromycin Flonase Levocarnitine Nitrostat Sumatriptan Alfuzosin Claritin Flovent Levocetirizine Nortriptyline Tacrine Aliskiren Clomipramine Fluoxetine Levodopa Oxybutynin Tadalafil Alprazolam Clonidine Fluticasone Lexapro Pamelor Tegretol Amitriptyline Clozapine Fluvoxamine Lioresal Pentasa Tekturna Anafranil Clozaril Fosamax Lisdexamfetamine Pepcid Tenex Antivert Cognex Fosinopril Lisinopril Periactin Thorazine Aripiprazole Combivir Gabapentin Lithium Piroxicam Tofranil Asacol Copegus Gemfibrozil Locholest Plaquenil Toprol Aspirin Cozaar Granisetron Loperamide Plendil Toradol Atarax Cyclobenzaprine Guanfacine Lopid Prevacid Trexall Atomoxetine Cymbalta Haldol Lopressor Prevalite UroXatral Atrovent Cyproheptadine Haloperidol Loratadine Prinivil Varenicline Azulfidine Cytotec Hydroxychloroquine Losartan ProAmatine Vasotec Baclofen Darifenacin Hydroxyzine Luvox Procardia Versed Biaxin Diflunisal Hyoscyamine Meclizine Propranolol Vistaril Budesonide Ditropan Ibuprofen Mesalamine -
Prazosin: Preliminary Report and Comparative Studies with Other
298 BRITISH MEDICAL JOURNAL 1 1 MAY 1974 Prazosin: Preliminary Report and Comparative Studies with Other Antihypertensive Agents Br Med J: first published as 10.1136/bmj.2.5914.298 on 11 May 1974. Downloaded from GORDON S. STOKES, MICHAEL A. WEBER British Medical Journal, 1974, 2, 298-300 bilirubin. One patient had minimal grade 3 hypertensive ocu- lar fundus changes, 10 had grade 1 or 2 changes, and four had normal fundi. Serum crea-tinine concentration was normal in Summary every patient. A diagnosis of uncomplicated essential hypertension was In a group of 14 hypertensive patients a 10-week course made in 12 patients. In two other patients pyelographic of treatment with prazosin 3-7 5 mg/day produced a signifi- evidence of analgesic nephropathy was found. The remaining cant reduction in mean blood pressure without serious side patient had essential hypertension and stable angina pectoris. effects. The fall in diastolic pressure exceeded the response After at least two baseline blood pressure readings, taken mm more to a placebo by 10 Hg or in 9 patients. The average when patients were recumbent and standing, treatment was decrease in diastolic pressure was similar to that produced started with prazosin, 1-mg capsules by mouth, three times or by methyldopa 750 mg/day propranolol 120-160 mg/day daily. Thereafter the patient visited the clinic at intervals of was but the fall in systolic pressure comparatively smaller, one to three weeks. At each visit blood pressure was meas- that the consistent with reported experimental work showing ured to the nearest 5 mm Hg with an Accoson sphygmomo- drug causes vasodilatation. -
Benign Prostatic Hyperplasia (BPH) Treatments Review 10/05/2009
Benign Prostatic Hyperplasia (BPH) Treatments Review 10/05/2009 Copyright © 2004 - 2009 by Provider Synergies, L.L.C. All rights reserved. Printed in the United States of America. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage and retrieval system without the express written consent of Provider Synergies, L.L.C. All requests for permission should be mailed to: Attention: Copyright Administrator Intellectual Property Department Provider Synergies, L.L.C. 5181 Natorp Blvd., Suite 205 Mason, Ohio 45040 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, -
Antiparasitic Properties of Cardiovascular Agents Against Human Intravascular Parasite Schistosoma Mansoni
pharmaceuticals Article Antiparasitic Properties of Cardiovascular Agents against Human Intravascular Parasite Schistosoma mansoni Raquel Porto 1, Ana C. Mengarda 1, Rayssa A. Cajas 1, Maria C. Salvadori 2 , Fernanda S. Teixeira 2 , Daniel D. R. Arcanjo 3 , Abolghasem Siyadatpanah 4, Maria de Lourdes Pereira 5 , Polrat Wilairatana 6,* and Josué de Moraes 1,* 1 Research Center for Neglected Diseases, Guarulhos University, Praça Tereza Cristina 229, São Paulo 07023-070, SP, Brazil; [email protected] (R.P.); [email protected] (A.C.M.); [email protected] (R.A.C.) 2 Institute of Physics, University of São Paulo, São Paulo 05508-060, SP, Brazil; [email protected] (M.C.S.); [email protected] (F.S.T.) 3 Department of Biophysics and Physiology, Federal University of Piaui, Teresina 64049-550, PI, Brazil; [email protected] 4 Ferdows School of Paramedical and Health, Birjand University of Medical Sciences, Birjand 9717853577, Iran; [email protected] 5 CICECO-Aveiro Institute of Materials & Department of Medical Sciences, University of Aveiro, 3810-193 Aveiro, Portugal; [email protected] 6 Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok 10400, Thailand * Correspondence: [email protected] (P.W.); [email protected] (J.d.M.) Citation: Porto, R.; Mengarda, A.C.; Abstract: The intravascular parasitic worm Schistosoma mansoni is a causative agent of schistosomiasis, Cajas, R.A.; Salvadori, M.C.; Teixeira, a disease of great global public health significance. Praziquantel is the only drug available to F.S.; Arcanjo, D.D.R.; Siyadatpanah, treat schistosomiasis and there is an urgent demand for new anthelmintic agents. -
2021 Step Therapy Criteria
SelectHealth Advantage 2021 Step Therapy Criteria Step Therapy Group Drug Name Criteria ACNE ADAPAL/BEN P Previous trial on at least ONE: AZELEX Generic topical acne treatment TRETINOIN ACTONEL RISEDRON SOD Previous trial on: RISEDRONATE alendronate ADAPALENE ADAPALENE Previous use of non-micronized tretinoin TAZAROTENE ANTICONVULSANT APTIOM Previous trial on at least TWO of the following: SPRITAM carbamezapine, divalproex, epitol, ethosuximide, felbamate, lamotrigine, XCOPRI levetiracetam, oxcarbazepine, phenytoin, tiagabine, topiramate, valproic acid, zonisamide ANTIDEPRESSION APLENZIN Previous trial on at least TWO of the following: EMSAM bupropion, citalopram, escitalopram, fluoxetine, fluvoxamine, maprotiline, FETZIMA mirtazapine, paroxetine, sertraline, venlafaxine, desvenlafaxine PEXEVA TRINTELLIX VIIBRYD ANTIPSYCHOTIC ARISTADA Previous trial on at least ONE of the following: ASENAPINE aripiprazole, clozapine, fluoxetine-olanzapine, haloperidol, olanzapine, FANAPT quetiapine, risperidone, ziprasidone LATUDA PALIPERIDONE SECUADO VRAYLAR BELSOMRA BELSOMRA Previous trial on at least ONE of the following: zaleplon, zolpidem, eszopiclone BUDESONIDE BUDESONIDE TAB Previous trial of ONE of the following: Mesalamine, Pentasa CADUET AMLOD/ATORVA Previous trial on at least ONE of the following: atorvastatin, lovastatin, pravastatin, simvastatin AND Previous trial on: amlodipine Updated 8/25/2021 1 SelectHealth Advantage 2021 Step Therapy Criteria Step Therapy Group Drug Name Criteria CAPEX CAPEX Previous trial on: clobetasol shampoo OR ciclopirox